HK Stock Market Move | ANTENGENE-B(06996) surged more than 8%, company founder and other management increased their holdings.
Dexin Pharmaceuticals - B (06996) rose over 8%, as of the time of writing, it increased by 8.55% to 4.57 Hong Kong dollars, with a turnover of 18.7563 million Hong Kong dollars.
ANTENGENE-B (06996) rose more than 8%, as of the time of reporting, up 8.55% to HK$4.57, with a turnover of HK$187.563 million.
On the news front, De Qi Pharmaceutical announced that the company's founder, executive director, CEO and chairman Mei Jianming purchased a total of 200,000 shares of the company through a controlled entity in the open market on March 23 and 24 at an average price of approximately US$0.512 (approximately HK$3.99) per share, representing approximately 0.029% of the total number of issued shares (excluding 202,500 shares of treasury stock). Following the purchase, Mei Jianming holds or is deemed to hold an interest in a total of 184 million shares, representing approximately 27.158% of the total number of issued shares.
In addition, the company's executive director and CFO Long Zhengguo purchased a total of 502,500 shares in the open market on March 23 and 24 at an average price of approximately HK$4.006 per share, representing approximately 0.074% of the total number of issued shares. Following the purchase, Long Zhengguo holds or is deemed to hold an interest in a total of 4.4825 million shares, representing approximately 0.66% of the total number of issued shares. The company's vice president and company secretary Cao Yang purchased shares in the open market on March 23 and 24 for a total consideration of HK$1.042 million. The total consideration paid by Mei Jianming, Long Zhengguo, and Cao Yang for the purchases of shares in the open market amounts to HK$3.853 million.
Related Articles

CSPC PHARMA (01093) announced its annual performance, with a net profit attributable to shareholders of 3.882 billion yuan, a decrease of 10.3% year-on-year. 5 external authorizations highlight innovative strength.
.png)
COSCO SHIPPING International (00517) releases annual results. Shareholders' net profit rose by 9% to HK$771 million.

ANTA SPORTS released its annual performance report in 2020, showing a 13.3% year-on-year increase in revenue to 80.219 billion yuan, with its market share in China rising to 21.8%.
CSPC PHARMA (01093) announced its annual performance, with a net profit attributable to shareholders of 3.882 billion yuan, a decrease of 10.3% year-on-year. 5 external authorizations highlight innovative strength.

COSCO SHIPPING International (00517) releases annual results. Shareholders' net profit rose by 9% to HK$771 million.
.png)
ANTA SPORTS released its annual performance report in 2020, showing a 13.3% year-on-year increase in revenue to 80.219 billion yuan, with its market share in China rising to 21.8%.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


